Inflammatory markers among adolescents and young adults with bipolar spectrum disorders

Journal of Clinical Psychiatry

Volumn 76, Issue 11, 2015, Pages 1556-1563

  Goldstein, Benjamin I ^a   Lotrich, Francis ^b   Axelson, David A ^c   Gill, Mary Kay ^b   Hower, Heather ^d   Goldstein, Tina R ^b   Fan, Jieyu ^b   Yen, Shirley ^d   Diler, Rasim ^b   Dickstein, Daniel ^d   Strober, Michael A ^e   Iyengar, Satish ^f   Ryan, Neal D ^b   Keller, Martin B ^d   Birmaher, Boris ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; AUTOMUTILATION; BIPOLAR DISORDER; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; SUICIDE ATTEMPT; YOUNG ADULT; BLOOD; INFLAMMATION;

ADOLESCENT; ADULT; BIOMARKERS; BIPOLAR DISORDER; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84958279880     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09395     Document Type: Article

References (51)

1. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078-1090. doi:10.408/JCP.08r04505 PubMed
2. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741. doi:10.1016/j.biopsych.208.1.029 PubMed
3. Mitchell RHB, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry. 2014;53(3):274-296. doi:10.1016/j.jac.2013.1.013 PubMed
4. Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47(4):321-332. doi:10.17/04867413478217 PubMed
5. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-817. doi:10.1016/j.neubiorev.2010.10.01 PubMed
6. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979. doi:10.1056/NEJM197040361401 PubMed
7. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(20):2528-2530. doi:10.101/jama.293.20.2528 PubMed
8. Munkholm K, Braüner JV, Kessing LV, et al. Cytokines in bipolar disorder vs healthy control subjects: a systematic review and metaanalysis. J Psychiatr Res. 2013;47(9):1119-1133. doi:10.1016/j.jpsychires.2013.05.018 PubMed
9. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):16-27. doi:10.1016/j.jad.2012.06.010 PubMed
10. Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15-25. doi:10.1016/j.biopsych.2013.01.07 PubMed
11. Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep. 2013;15(12):425. doi:10.107/s1920-013-0425-9 PubMed
12. Goldstein BI, Collinger KA, Lotrich F, et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21(5):479-484. doi:10.1089/cap.201.09 PubMed
13. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(10):1139-1148. doi:10.101/archpsyc.63.10.139 PubMed
14. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(2):175-183. doi:10.101/archpsyc.63.2.175 PubMed
15. Birmaher B, Axelson D, Goldstein B, et al. Fouryear longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry. 2009;166(7):795-804. doi:10.176/api.ajp.209.08101569 PubMed
16. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. doi:10.1097/04583-197070-021 PubMed
17. Axelson D, Birmaher BJ, Brent D, et al. A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Mania Rating Scale for children and adolescents. J Child Adolesc Psychopharmacol. 2003;13(4):463-470. doi:10.1089/104546032724850 PubMed
18. Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by semistructured interview: test-retest reliability of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present Episode version. Arch Gen Psychiatry. 1985;42(7):696-702. doi:10.101/archpsyc.1985.01790306408 PubMed
19. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540-548. doi:10.101/archpsyc.1987.0180180509 PubMed
20. Axelson DA, Birmaher B, Strober MA, et al. Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified. Adolesc Psychiatry. 2011;50(10):1001-1016. doi:10.1016/j.jac.201.07.05
21. Weissman MM, Wickramaratne P, Adams P, et al. Brief screening for family psychiatric history: the Family History Screen. Arch Gen Psychiatry. 2000;57(7):675-682. doi:10.101/archpsyc.57.7.675 PubMed
22. Hollingshead A. Four-Factor Index of Social Status. New Haven, CT: Yale University; 1975.
23. Shaffer D, Gould MS, Brasic J, et al. A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228-1231. doi:10.101/archpsyc.1983.017901074010 PubMed
24. Ogden CL, Flegal KM. Changes in terminology for childhood overweight and obesity. Natl Health Stat Report. 2010;25(25):1-5. PubMed
25. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002;246(246):1-190. PubMed
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
27. Remlinger-Molenda A, Wojciak P, Michalak M, et al. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology. 2012;66(3):193-198. doi:10.159/03949 PubMed
28. Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1-3):261-265. doi:10.1016/j.schres.207.03.02 PubMed
29. Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608-1616. doi:10.1016/j.jpsychires.201.08.03 PubMed
30. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry. 2003;53(2):157-165. doi:10.1016/S06-323(02)01452-X PubMed
31. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251. doi:10.101/archgenpsychiatry.201.12 PubMed
32. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457. doi:10.1016/j.biopsych.209.09.03 PubMed
33. Copeland WE, Shanahan L, Worthman C, et al. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry. 2012;71(1):15-21. doi:10.1016/j.biopsych.201.09.023 PubMed
34. Lotrich FE, Ferrell RE, Rabinovitz M, et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344-348. doi:10.1016/j.biopsych.208.08.09 PubMed
35. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197(5):372-377. doi:10.192/bjp.bp.109.076430 PubMed
36. Matthews KA, Schott LL, Bromberger JT, et al. Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women? Brain Behav Immun. 2010;24(1):96-101. doi:10.1016/j.bi.209.08.05 PubMed
37. Barbosa IG, Huguet RB, Mendonça VA, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(2):139-143. doi:10.107/s0406-010-016-z PubMed
38. Tsai SY, Yang YY, Kuo CJ, et al. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64(2-3):185-193. doi:10.1016/S0165-0327(0)0252-4 PubMed
39. Cetin T, Guloksuz S, Cetin EA, et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry. 2012;12(1):158. doi:10.186/1471-24X-12-158 PubMed
40. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7(10):1107-1114. doi:10.1038/sj.mp.401084 PubMed
41. Kim Y-K, Myint A-M, Lee B-H, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129(3):267-272. doi:10.1016/j.psychres.204.08.05 PubMed
42. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447-458. doi:10.1017/S14614570809310 PubMed
43. Janelidze S, Mattei D, Westrin A, et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25(2):335-339. doi:10.1016/j.bi.2010.10.010 PubMed
44. Waldschmidt TJ, Cook RT, Kovacs EJ. Alcohol and inflammation and immune responses: summary of the 2006 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2008;42(2):137-142. doi:10.1016/j.alcohol.207.1.03 PubMed
45. Halpern JH, Sholar MB, Glowacki J, et al. Diminished interleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration. J Clin Endocrinol Metab. 2003;88(3):1188-1193. doi:10.1210/jc.202-020804 PubMed
46. Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152(5):649-654. doi:10.1038/sj.bjp.0707458 PubMed
47. Mandrekar P, Bala S, Catalano D, et al. The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol. 2009;183(2):1320-1327. doi:10.4049/jimunol.0803206 PubMed
48. Danese A, Moffitt TE, Pariante CM, et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65(4):409-415. doi:10.101/archpsyc.65.4.409 PubMed
49. Khaodhiar L, Ling PR, Blackburn GL, et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr. 2004;28(6):410-415. doi:10.17/014860710402806410 PubMed
50. Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64(10):896-900. doi:10.1016/j.biopsych.208.05.019 PubMed
51. Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17(4):276-285. doi:10.1016/S089-1591(03)057-6 PubMed